Jefferies Financial Group reaffirmed their hold rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) in a research report report published on Tuesday, Marketbeat reports. They currently have a $21.00 price target on the stock, up from their prior price target of $10.00. FUSN has been the topic of several other reports. William Blair […]